Saturday Reverie

My dogs are barking.
On this early Saturday morning.

Gosh, February is near!
And I still haven't written here.

January entries, too personal
To be seen in this OPEN journal.

So let me start,
By NOT trying to be smart.

Oh, words, please come out from your cage.
And help me fill this page.

Hahaha. I'm having fun now.
In making lines rhyme somehow.

The birds are chirping;
And I'm just typing.

I hear thunder.
Will there be rain? I wonder.

Now, I'm really having fun
Even if there's no SUN.

My stomach is grumbling.
But it's too early to be feasting.

Pandesal... pandedal, shouts a passing boy.
Not too loud, boy, or my wife you will annoy.










Gem is still asleep,
So I'll set my text TONE to a beep.

Oh, what a hectic week!
Glad I was not sick.

Damn, why the need
To be on lightning speed?

Is it a must,
To always run fast?

Or is going out of town
Wearing me down?










I guess, The hardest part
Would be not to take part.

Because if I just stand still
There wouldn't be any thrill.

So the biggest question to ask today:
Will there be an American Idol replay?

And our dogs are barking.
On this wonderful Saturday morning.

GSK News

Just read this:

GlaxoSmithKline to acquire UCB portfolio for $666 million

LONDON (MarketWatch) --

GSK said Friday that it has signed a deal with UCB to acquire its current marketed product portfolio across certain territories in Africa, the Middle East, Asia Pacific and Latin America for 515 million euros ($666 million) in cash. GSK said the deal includes the drugs Keppra, Xyzal and Zyrtec and will strengthen its product portfolio in emerging markets. Completion of the deal is expected to take place in March. UCB said it will continue to strengthen its core businesses, such as immunology.

----------------

UCB receives lb515 Million from GSK

Friday 23rd January 2009

UCB has agreed with GlaxoSmithKline (GSK), to sell current UCB business and UCB affiliates in selected emerging markets for a cash compensation of €515 million upon closing of the transaction expected in late March 2009.

The commercial operations and product distribution rights to be acquired by GSK represent approximately 3-4% of UCB's 2008 expected revenue of at least €3.3 billion.

The agreement includes more than 50 UCB operations in the following geographic regions: Far-East, Middle-East, Latin America and Africa. This agreement does not include among other countries: Brazil, Russia, India, China, South-Korea or Mexico which are considered by UCB as strategic emerging markets.

The agreement covers principally all currently marketed UCB products and staff in the regions mentioned above. It does not include UCB's new core products such as Vimpat (lacosamide), Neupro (rotigotine), Cimzia (certolizumab pegol), nor does it provide rights to any of UCB's research & development pipeline programmes.

"This is a win-win agreement", said Roch Doliveux, CEO of UCB.

"Consistent with our core strategies outlined by the SHAPE programme, UCB focuses on its core areas while GSK acquires assets which fit with its growth and diversification strategy. UCB will continue to strengthen its core indication areas CNS and immunology and its presence in its key strategic markets to bringing new medicines to patients who suffer from serious diseases."